Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced a partnership with Nanosoft Polymers to initiate polymer process development and analytical characterization activities for ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The collaboration is part of Onco-Innovations' chemistry, manufacturing, and controls (CMC) strategy to establish a scalable, reproducible, and analytically characterized polymer platform.
The work scope includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement, and manufacturing scalability assessments. These activities are intended to support future formulation, manufacturing, regulatory, and clinical development of ONC010. The company stated that Nanosoft's expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform and support future GMP manufacturing readiness.
Onco-Innovations is a Canadian-based company focused on cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. The advancement of ONC010's manufacturing development marks a critical step toward bringing this potential treatment to patients.
For more details, the full press release is available at https://nnw.fm/BeSoS. The latest news and updates regarding ONNVF can be found in the company's newsroom at https://nnw.fm/ONNVF.
